Vortex Launches Clinical Study Using Liquid Biopsy Technology to Advance Cancer Monitoring
The study will explore how live circulating tumour cells captured from a blood sample can help doctors monitor treatment response and disease progression
Vortex Liquid Biopsy Solutions Ltd (‘Vortex’, or ‘the Company’), a leading oncology liquid biopsy company, is pleased to announce a new clinical study with The Doctors Laboratory (TDL) Trials to assess how its proprietary technology could transform the way breast cancer is monitored and treated.
The study will take place at TDL’s state-of-the-art facilities in the HALO Building, London, and will involve a cohort of patients with progressive cancer. It will focus on how effectively Vortex’s liquid biopsy technology can capture and analyse live circulating tumour cells (CTCs) directly from blood samples, enabling detailed characterisation of biomarkers to inform cancer progression and treatment response.
Unlike traditional biopsies that require surgical removal of tumour tissue, Vortex’s technology allows clinicians to capture intact, living cancer cells directly from whole blood. Within about an hour, the system isolates these cells at high purity and yield, preserving their natural state for advanced analysis. This approach gives clinicians and researchers a clearer view of how cancer is evolving in real time, supporting more informed decisions around therapy selection and disease monitoring.
The study will be supported by AxonDx, Vortex’s strategic partner. Axon will apply its AI-powered analysis tools to interpret the captured cells and deliver deeper biological insights. This important clinical study aims to demonstrate how combining live-cell isolation with advanced analytics could pave the way for more personalised and responsive cancer care.
Dr. Paul Reeves, Managing Director of Vortex, said:
“Cancer is a leading cause of death worldwide and while treatments have advanced significantly, clinicians still need better ways to track how the disease is responding in real time. This study is an important step in showing how live circulating tumour cells can give doctors that insight, helping to refine treatment choices and improve outcomes for patients.”
Nigel Brooksby, Non-Executive Chairman of Vortex, added:
“This collaboration brings together clinical excellence and cutting-edge technology to address a growing global health need. Partnering with TDL, a leader in clinical laboratory services, allows us to generate the real-world evidence needed to bring liquid biopsy testing into routine clinical use and make precision medicine more accessible worldwide.”
